Publications

See Publication

Identification of apilimod.

Identification of apilimod as a first-in-class PIKfyve kinase inhibitor for treatment of B-cell non-Hodgkin lymphoma

Sophia Gayle, Sean Landrette, Neil Beeharry, Chris Conrad, Marylens Hernandez, Paul Beckett, Shawn M. Ferguson, Talya Mandelkern, Meiling Zheng, Tian Xu, Jonathan Rothberg and Henri Lichenstein

Blood Journal 2017
Supplemental methods, figures, and data
See Publication

B-cell non-Hodgkin lymphoma.

B-cell non-Hodgkin lymphoma: Selective vulnerability to PIKFYVE inhibition

Sophia Gayle, Sean Landrette, Neil Beeharry, Chris Conrad, Marylens Hernandez, Paul Beckett, Shawn M. Ferguson, Talya Mandelkern, Meiling Zheng, Tian Xu, Jonathan Rothberg and Henri Lichenstein

Autophagy 2017
See Publication

Targeted therapy in lymphoma.

Toward autophagy-targeted therapy in lymphoma

Lapo Alinari

Blood Journal 2017
See Publication

ASH 2017

Phase 1 Clinical Safety, Pharmacokinetics (PK), and Activity of Apilimod Dimesylate (LAM-002A), a First-in-Class Inhibitor of Phosphatidylinositol-3-Phosphate 5-Kinase (PIKfyve), in Patients with Relapsed or Refractory B-Cell Malignancies

Wael A Harb, Catherine S Diefenbach, Nehal Lakhani, Sarah C Rutherford, Marshall T Schreeder, Stephen M. Ansell, Taimur Sher, David M Aboulafia, Jonathon B Cohen, Darrell Nix, Sean Landrette, Kate Flanders, Langdon L Miller, Henri Lichenstein and Jeremy S. Abramson

Blood Journal